Autologous Cell Therapy Market Estimated to Grow USD 34.7 Billion by 2027, Rising at a 18.1% CAGR- Transparency Market Research, Inc.
21 août 2024 11h09 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. , Aug. 21, 2024 (GLOBE NEWSWIRE) -- According to Transparency Market Research (TMR), the global autologous cell therapy market...
Medical Education Market is Projected to Expand at 5.1% CAGR, Reaching US$ 57.95 Billion by 2034 | Fact.MR
19 août 2024 07h00 HE
|
FACT.MR
Rockville, MD, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Revenue from medical education is estimated to reach US$ 35.11 billion in 2024, as revealed in a study recently updated by Fact.MR, a market research...
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
09 août 2024 11h00 HE
|
Tevogen Bio Inc
Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
24 juil. 2024 08h00 HE
|
Halberd Corp.
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
Tissue Engineering Market Size is Expected to Reach USD 12.43 Billion by 2032, Growing at a CAGR of 14.40%: Straits Research
18 juil. 2024 10h20 HE
|
Straits Research Private Limited - Garner Insights
New York, United States, July 18, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global tissue engineering market size was valued at USD 4,333.61 million in 2023. It is...
Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Small-Molecule Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index
16 juil. 2024 07h30 HE
|
Seyltx, Inc.
- Results will be presented at the London International Cough Symposium on July 18, 2024 - Dose dependent cough suppression to >90% in vivo with no effect on basal respiratory rates - Multiple...
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
10 juil. 2024 08h05 HE
|
Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
United States Neurology KOLs Fair-Market Value Compensation Rates Report: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)
10 juil. 2024 05h18 HE
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering. Thought Leader...
Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough
09 juil. 2024 07h30 HE
|
Seyltx, Inc.
- Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult patients in the USA were analyzed for cough-related diagnoses and treatments in the EHR...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
26 juin 2024 19h05 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...